Publication

Article

Pharmacy Times

November 2022
Volume88
Issue 11

Low Rates of Flu, Pneumococcal Vaccine Raise Concerns for Experts

The results of a new survey showed that 49% of adults in the United States will get a vaccine for the 2022 and 2023 influenza season, according to the National Foundation for Infectious Diseases (NFID). These data were released at the 2022 NFID Influenza/Pneumococcal Disease News Conference.

During the conference, Rochelle Walensky, MD, MPH, director of the CDC, said clinicians should strongly urge eligible patients to receive a flu vaccine, especially those aged 65 years and older. She recommends that adults in the United States who are older than 65 years get a higher-dose adjuvant flu vaccine, as data show it could be more effective.

The 2020 and 2021 influenza seasons were mild because of the COVID-19 pandemic. However, data from Australia suggest the new season may be significantly stronger.

The NFID commissioned a national survey to learn who would get vaccinated, finding that 1 in every 5 adults at severe risk of influenza will not. However, just 29% of those at risk were advised to get vaccinated. Of those, 74% were subsequently vaccinated. This could indicate that clinicians play a key role in education and advising individ-uals about flu vaccination, according to Patricia Stinchfield, RN, MS, CPNP, president of the NFID.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: komokvm | stock.adobe.com
Children's doctor vaccinating little boy at home.
Covid-19 Vaccine New Variant 2024-2025 | Image Credit: New Africa - stock.adobe.com
COVID-19 vaccine 2024-2025 Season | Image Credit: Alernon77 - stock.adobe.com
Vaccinating an elderly person.
Doctor hands making a vaccination in the shoulder of patient